Author

M. E. Abernathy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 4 Organism:human· 3 Assay:proteomics· 2 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Organism:non-human primate· 1 Assay:structural biology· 1

Frequent Co-Authors

M. C. Nussenzweig· 3 shared P. J. Bjorkman· 3 shared A. Gazumyan· 2 shared C. O. Barnes· 2 shared H. B. Gristick· 2 shared J. R. Keeffe· 2 shared M. A. Martin· 2 shared M. S. Seaman· 2 shared

Activity by Year

2021-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

M. C. Nussenzweig

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Human neutralizing antibodies to cold linear epitopes and to subdomain 1 of SARS-CoV-2

F. Bianchini, V. Crivelli, M. E. Abernathy, C. Guerra, M. Palus, J. Muri, H. Marcotte, A. Piralla, M. Pedotti, R. De, L. Simonelli, M. Matkovic, C. Toscano, M. Biggiogero, V. Calvaruso, , Ru

The paper identifies broadly cross-reactive neutralizing antibodies against SARS-CoV-2 variants using coldspot-guided antibody discovery.

bioRxiv · Nov 24, 2022 · PreprintImmunology

CD4-binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wildtype animals

H. B. Gristick, H. Hartweger, M. Loewe, J. van Schooten, V. Ramos, T. Y. Oliviera, Y. Nishimura, N. S. Koranda, A. Wall, K.-H. Yao, D. Poston, A. Gazumyan, M. Wiatr, M. Horning, J. R. Keeffe, , P. J. Bjorkman

This study shows that CD4bs immunogens can elicit potent, broad anti-HIV-1 neutralizing antibodies in transgenic and wildtype animals.

bioRxiv · Sep 8, 2022Immunology

Human anti-ACE2 monoclonal antibodies as pan-sarbecovirus prophylactic agents

F. Zhang, J. Jenkins, R. V. H. de Carvalho, S. Nakandakari-Higa, T. Chen, M. E. Abernathy, E. Nyakatura, D. Andrew, I. V. Lebedeva, I. C. Lorenz, H.- H. Hoffmann, C. M. Rice, G. D. Victora, C. O. Barnes, T. Hatziioannou, P. D. Bieniasz

The paper develops human monoclonal antibodies targeting the ACE2 receptor to block infection by SARS-CoV-2 and related sarbecoviruses, showing broad efficacy against variants and no adverse effects on ACE2 function.

bioRxiv · Aug 24, 2022 · PreprintMicrobiology

Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide and destroys a neutralizing epitope

M. E. Abernathy, H. B. Gristick, J. Vielmetter, J. R. Keeffe, P. N. Gnanapragasam, Y. E. Lee, A. Escolano, R. Gautam, M. S. Seaman, M. A. Martin, M. C. Nussenzweig, P. J. Bjorkman

This study identifies an off-target antibody that displaces the HIV-1 Env fusion peptide and blocks neutralizing epitopes, providing insights for vaccine design.

bioRxiv · Mar 17, 2021Immunology

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Z. Wang, F. Schmidt, Y. Weisblum, F. Muecksch, C. O. Barnes, S. Finkin, D. Schaefer-Babajew, M. Cipolla, C. Gaebler, J. A. Lieberman, T. Y. Oliveira, Z. Yang, M. E. Abernathy, K. E. Huey-Tubman, A. Hurley, , M. C. Nussenzweig

This study examines antibody and memory B cell responses to mRNA vaccines against SARS-CoV-2 and assesses their effectiveness against emerging variants.

Nature · Feb 10, 2021Peer-reviewedImmunology